Click HERE to register for a LIVE presentation from industry experts Pierre d’Epenoux and Paul Frohna (PhD) on ImCheck: Exploring two uncharted territories in immunomodulation, butyrophilins and gamma-delta T cells.
ImCheck Therapeutics is designing and developing a new generation of immunotherapy antibodies positioned at the crossroads of two high-potential immunological fields: γ9δ2 T cells and a novel super-family of immunomodulators, butyrophilins. Due to their mechanism of action, and notably their ability to simultaneously modulate innate and adaptive immunity, ImCheck’s “first-in-class” activating antibodies may be able to produce superior clinical results in a range of oncology indications as compared to the first-generation of immune checkpoint inhibitors and when used in combination to overcome the resistance to this group of agents. ImCheck’s lead program, ICT01, a first-in-class γδ T cell-activating monoclonal antibody, entered the clinic in 2020. The EVICTION Phase I/IIa clinical trial is evaluating ICT01 in patients with advanced, refractory cancers, including solid and liquid tumor indications. In addition to a number of oncology-focused antibodies moving toward the clinic, preclinical experiments with ImCheck’s antagonist antibodies have demonstrated potential as treatments for a wide range of autoimmune diseases.
ImCheck Therapeutics has raised over $88 million (€74 million) in two rounds of venture capital financing from an international syndicate. ImCheck’s €20 Million Series A financing was led by Boehringer Ingelheim Venture Fund (BIVF), Kurma Partners, and Idinvest and joined by Gimv and Life Sciences Partners. Its €54 million Series B was led by Bpifrance and Pfizer Ventures, with BB Pureos, Wellington Partners, Agent Capital and Alexandria Venture Investments as well as the investors from ImCheck’s Series A joining the round. Co-founder of the Marseille Immunopole cluster, ImCheck benefits from support from Prof. Daniel Olive (INSERM, CNRS, Institut Paoli Calmettes, Aix-Marseille Université), a worldwide leader in γδ T cells and butyrophilins research.